Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function

Area of Science:

• Nephrology
• Immunosuppression
• Transplantation

Background:

• Basiliximab is an effective treatment for acute rejection in renal transplantation.
• Delayed graft function (DGF) is a risk factor for acute rejection and reduced graft survival.
• This study investigated basiliximab's impact on DGF in high-risk renal transplant recipients.

Purpose of the Study:

• To evaluate the efficacy of basiliximab in preventing delayed graft function (DGF) in renal transplant recipients at high risk.
• To assess the safety and tolerability of basiliximab in this patient population.

Main Methods:

• A cohort of 87 renal transplant patients were studied, with 42 receiving basiliximab and 45 serving as a control group.
• Patients received standard immunosuppression including cyclosporine or tacrolimus, mycophenolate mofetil, and steroids.
• Delayed graft function (DGF) was defined by the need for dialysis within the first week or failure to improve renal function.

Main Results:

• The incidence of DGF was lower in the basiliximab group (43%) compared to the control group (62%), though not statistically significant (P = .07).
• Excluding non-heart-beating donors, DGF incidence was significantly reduced in the basiliximab group (38% vs. 62%, P = .04).
• Regression analysis identified basiliximab as a protective factor against DGF (0.26; 0.09-0.76).

Conclusions:

• Basiliximab significantly reduced DGF incidence in high-risk renal allograft recipients.
• The drug was well-tolerated with no reported adverse events.
• Basiliximab is a potential therapeutic option for patients at high risk of DGF undergoing renal transplantation.